Rare and Orphan Disease Trials

Long-Term Efficacy Data in Rare Disease Gene Therapy Programs

Posted on digi By digi

Gene therapy has emerged as a transformative treatment for rare diseases, offering the possibility of one-time interventions that deliver lasting clinical benefit. However, regulators, clinicians, and patients alike require proof that these therapies provide durable efficacy and sustained safety over years or even decades. Unlike conventional drugs, where repeated dosing provides long-term outcome data, gene therapies require robust follow-up protocols to confirm their lasting effectiveness.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Ethical Considerations in Pediatric Rare Disease Trials

Posted on digi By digi

Conducting clinical trials in pediatric populations with rare diseases presents a unique set of ethical, regulatory, and operational challenges. These children often suffer from severe, progressive, or life-threatening conditions with limited or no existing treatment options, which amplifies the urgency for clinical research. However, children are considered a vulnerable population under regulatory frameworks such as ICH E6(R2), FDA 21 CFR 50 Subpart D, and the EU Clinical Trials Regulation.
Click to read the full article.

Ethics & Patient Engagement, Rare and Orphan Disease Trials

Cold Chain Logistics for Rare Disease Biological Samples

Posted on digi By digi

In rare and ultra-rare disease trials, biological samples such as blood, cerebrospinal fluid (CSF), urine, tissue biopsies, or genetic material are often irreplaceable. These samples are typically used for biomarker analysis, genomic sequencing, pharmacokinetic (PK) profiling, or central laboratory testing. Given the low number of enrolled patients, every sample carries substantial scientific value—making cold chain logistics an operational and regulatory priority.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Ethical Considerations in Non-Treatment Observational Studies

Posted on digi By digi

Non-treatment observational studies, including natural history studies and patient registries, are vital in rare disease research. These studies do not involve investigational drugs or interventions, yet they collect sensitive longitudinal data from vulnerable populations—often children or patients with severely disabling conditions. As such, they pose unique ethical challenges that go beyond standard data collection practices.
Click to read the full article.

Natural History Studies, Rare and Orphan Disease Trials

Case Study: Overcoming Recruitment Barriers in Rare Disease Trials

Posted on digi By digi

Recruitment remains the single most critical challenge in rare disease clinical trials. With patient populations often numbering in the hundreds—or even dozens—globally, traditional recruitment approaches used in large-scale trials are ineffective. Barriers such as delayed diagnosis, limited clinical expertise, geographic dispersion, and lack of awareness significantly delay trial initiation and completion. These obstacles increase trial costs, risk under-enrollment, and can ultimately threaten the viability of drug development programs.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Bridging Natural History and Interventional Studies in Rare Diseases

Posted on digi By digi

Natural history studies provide critical insight into disease progression, phenotypic variability, and baseline clinical trajectories. In rare disease research, where randomized controlled trials (RCTs) may not always be feasible, these observational datasets serve as a foundation for designing interventional studies. Bridging the two paradigms—non-interventional and interventional—is essential for efficient, ethically sound, and scientifically robust clinical development.
Click to read the full article.

Natural History Studies, Rare and Orphan Disease Trials

First-in-Class Treatment Approval for Rare Cardiac Disorder

Posted on digi By digi

Rare cardiac disorders, such as restrictive cardiomyopathy or inherited arrhythmia syndromes, often lack established treatment options due to their low prevalence and highly variable clinical presentation. These conditions frequently lead to early mortality, poor quality of life, and limited therapeutic interventions. Developing a first-in-class therapy for such a disease is a monumental achievement, both scientifically and regulatorily, as it addresses unmet medical needs while setting precedent for future drug development. Regulatory agencies, including the FDA and EMA, often grant orphan drug designation, breakthrough therapy designation, or priority review to accelerate access to patients.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Biomarker Discovery and Validation in Rare Disease Trials

Posted on digi By digi

In rare disease drug development, where traditional clinical endpoints are often lacking or difficult to measure, biomarkers serve as essential tools for diagnosis, patient stratification, disease monitoring, and evaluating treatment effects. Biomarkers may include genetic mutations, protein levels, metabolites, imaging markers, or digital health metrics—each offering a unique lens into disease biology.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Compassionate Use and Expanded Access in Rare Disease Therapies

Posted on digi By digi

For patients with rare and life-threatening diseases, conventional treatment options are often limited or nonexistent. When clinical trial participation is not feasible due to geographic, medical, or eligibility limitations, compassionate use—or expanded access—offers a critical alternative pathway for accessing investigational therapies outside of clinical trials. These programs allow patients to receive potentially life-saving treatments before formal regulatory approval, under strict conditions and ethical oversight.
Click to read the full article.

Ethics & Patient Engagement, Rare and Orphan Disease Trials